BioMarin submits CTA for BMN-190 for Batten disease

theflyonthewall.com

BioMarin announced that it has submitted a Clinical Trial Application with the Medicines and Healthcare Products Regulatory Agency in the U.K. for BMN-190, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The company expects to start enrolling patients in a Phase 1/2 trial in mid-2013.

Rates

View Comments (0)